The implementation of the EUDAMED Vigilance and Post-Market Surveillance module appears likely to be delayed beyond the previously anticipated Q2 2027 timeline. Advena understands that, following inconclusive audit results, a further audit will be required before the module can be formally declared functional and the process towards mandatory use can proceed. On this basis, mandatory ...